Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Innovation and Product Development news
16 June 2026
Covestro launches EU-backed Bio4PURConti to scale continuous bio-based aniline production
EU project to deliver the first continuous process for bio-based aniline, aiming 1.5 m³ semi-industrial demos and a 100% plant-carbon, drop-in MDI feedstock.
16 June 2026
thyssenkrupp Uhde completes İGSAŞ ammonia converter cartridge and catalyst replacement
Restored 1,200 mtpd capacity with 13% production gain while running at 7% lower synthesis pressure and 70% lower converter pressure drop, cutting specific energy use.
16 June 2026
Phelan Green selects Johnson Matthey for eSAF plant in South Africa
Licensing secures HyCOgen and FT CANS technologies for a Saldanha Bay eSAF facility; first phase aims 35,000 t/yr for EU/UK markets, with full build to 140,000 t/yr.
16 June 2026
Evonik launches ISCC Plus‑certified ULTRASIL® eCO from Adapazarı site
Circular precipitated silica from ISCC Plus‑certified feedstock for tire and rubber applications; mass-balance verified and now commercially produced in EMEA.
16 June 2026
Sinopec selected for 2026 low‑carbon case
Chosen among 28 'Finding Zero‑Carbon Factories' cases for 2026; honoured for 16 consecutive years and highlighted for projects, capacity and efficiency measures.
16 June 2026
Mitsubishi Chemical’s DURABIO chosen for Audi Q3 door switch inserts
Selected for single-component door switch panels in the new Audi Q3, offering three textures, mold-in-color piano black and reduced painting, VOCs and CO₂ emissions.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
15 June 2026
Takeda’s oveporexton improved function, cognition and nighttime sleep in narcolepsy type 1
Phase 3 secondary/exploratory endpoints showed benefits across daily functioning, cognitive measures and REM sleep patterns; NDA has Priority Review with a Q3 PDUFA goal date.
15 June 2026
UPM Adhesive Materials 2025 Climate Review: emissions cuts and value-chain collaboration
58% cut in scope 1–2 emission intensity vs 2015, expanded supplier carbon data, product footprints cover ~94% of label sales, and recycling services support release liner waste recovery.
15 June 2026
Croda’s Avanti Polar Lipids partners with NovoArc to expand lipid offering for pharma research
Adds advanced lipid technologies offering improved stability and enabling new delivery routes for mRNA, protein and peptide therapeutics; initially for research use with scale-up development.
15 June 2026
LKAB granted environmental permit for expanded Malmberget operations
Court allows continued and expanded mining and processing in Malmberget, including a demo fossil-free sponge iron plant and an apatite processing line for Luleå supply.
15 June 2026
Mitsui Chemicals — Developing Dental Materials M&A as a Third Growth Pillar
Acquire Ultradent to build a US dental materials platform, lift L&HC to ¥86bn by FY30 (ROS 17%), and capture whitening growth amid broader specialty-chemicals repositioning.
14 June 2026
Lilly: Jaypirca plus venetoclax‑rituximab lowers progression risk 45% in relapsed/refractory CLL/SLL
Phase 3 BRUIN CLL-322 found adding pirtobrutinib to a two‑year venetoclax+rituximab regimen reduced progression or death by 45% versus venetoclax+rituximab alone.
13 June 2026
Lilly reports Phase 1 results for AJ1-11095, a first‑in‑class type II JAK2 inhibitor
Phase 1 data show 70% SVR35 and TSS50 rates, VAF reductions in 21/23 patients, no dose‑limiting toxicities; expansion and further indications planned.
13 June 2026
Johnson & Johnson: TALVEY plus DARZALEX FASPRO shows superior PFS and OS in Phase 3 MonumenTAL‑3
GPRC5D bispecific plus anti‑CD38 combo cut progression risk and delivered 24‑month PFS up to 81% and OS up to 89% in earlier‑line relapsed/refractory multiple myeloma.
13 June 2026
Genmab: Epcoritamab shows high response rates in elderly first‑line DLBCL with mono and R‑mini‑CHOP regimens
Fixed‑duration subcutaneous epcoritamab produced rapid, durable responses and high MRD negativity in elderly newly diagnosed DLBCL patients ineligible for full‑dose anthracycline therapy.
12 June 2026
Roche VENTANA PTEN (SP218) FDA-cleared as PTEN companion diagnostic in prostate cancer
First FDA-cleared IHC companion diagnostic to detect PTEN protein loss and select patients for capivasertib (TRUQAP) plus abiraterone therapy.
12 June 2026
Merck: FDA approves KEYTRUDA and KEYTRUDA QLEX with WELIREG for adjuvant ccRCC
FDA cleared PD‑1 plus HIF‑2α adjuvant regimens after Phase 3 showed 28% lower recurrence risk and 81% vs 74% 24‑month DFS; notable anemia, hypoxia and treatment discontinuations.
12 June 2026
BASF’s Tinosorb S (bemotrizinol) approved by FDA as first new U.S. sunscreen active in 27 years
FDA clears bemotrizinol, a broad‑spectrum, photostable UV filter that enables longer‑lasting, stronger UVA/UVB protection and improved formulation stability.
12 June 2026
Chugai files Tecentriq for maintenance therapy after definitive chemoradiotherapy in locally advanced esophageal cancer
Submission seeks approval of an anti‑PD‑L1 agent as maintenance therapy after definitive chemoradiotherapy, supported by SKYSCRAPER‑07 Phase III interim results.
12 June 2026
GSK’s momelotinib gains orphan drug status in US and EU for VEXAS
Orphan designations back development of momelotinib for VEXAS; ATLAS phase II/III underway with design to be shown at EHA 2026.
11 June 2026
Genmab: Epcoritamab plus R2 shows consistent benefit across EPCORE FL‑1 subgroups
Post‑hoc subgroup analysis of the Phase 3 EPCORE FL‑1 shows epcoritamab+rituximab+lenalidomide delivers consistent PFS, ORR and CRR gains with a manageable safety profile across risk and fitness subgroups.
11 June 2026
Novo Nordisk: Wegovy pill approved in UK as first daily GLP-1 weight-loss tablet in Europe
Daily 25 mg semaglutide tablet approved as adjunct to diet and exercise for adults with obesity or overweight plus a weight‑related condition; private prescriptions expected soon.
11 June 2026
Johnson & Johnson’s IMAAVY shows rapid, durable hemoglobin gains in Phase 2/3 wAIHA trial
Nipocalimab 30 mg/kg produced rapid hemoglobin rises and ~3× more durable responders versus placebo at 24 weeks, with early fatigue improvement and reduced steroid use.
11 June 2026
Takeda's zasocitinib outperforms deucravacitinib in Phase 3 psoriasis head-to-head
Once-daily oral TYK2 inhibitor showed statistical superiority to deucravacitinib for PASI100 and key secondary endpoints, with >35% achieving complete skin clearance at week 16.
11 June 2026
Evonik launches low‑carbon peracetic acid for Europe
Peracetic acid produced using bio-based acetic acid and low‑carbon hydrogen peroxide; mass‑balance accounting lets customers lower Scope 3 emissions transparently.
10 June 2026
Genentech: FDA grants Priority Review for Tecentriq plus chemotherapy in stage III dMMR/MSI‑H colon cancer
FDA accepted an sBLA for adjuvant PD‑L1 therapy plus chemotherapy in stage III dMMR/MSI‑H colon cancer; agency decision expected Oct 9, 2026.
10 June 2026
Aptar N‑Sorb patent allowed by USPTO for packaging-based nitrosamine mitigation
USPTO allowed a patent for N‑Sorb, a packaging material that reduces nitrosamines across multiple APIs and may support FDA Orange Book strategies.
10 June 2026
dsm-firmenich: FDA approves bemotrizinol (PARSOL® Shield) for U.S. suncare
FDA clears bemotrizinol (PARSOL® Shield), the first new U.S. sunscreen active in 25+ years, enabling broad‑spectrum, photostable formulas with low‑concentration efficacy.
10 June 2026
Evonik opens pilot plant for high-performance AEM membrane
Pilot-scale polymer membrane production for AEM electrolysis targets up to 2.5 GW/year, enabling lower-cost green hydrogen and manufactured without PFAS.
10 June 2026
Evonik advances chemical recycling with Purocel adsorbents and modular units
Improves pyrolysis-oil quality for steam crackers by removing chlorine, nitrogen and silicon; specific adsorbents cut chlorides up to threefold and modular columns enable flexible plant integration.
Next →
